

## PANCURONIUM

<b>PRESENTATION:</b>	Ampoules containing 4mg/2ml
<b>INDICATION:</b>	Muscle relaxation.  Non-depolarising neuromuscular blocking agent with a long duration of action.
<b>DOSE AND ADMINISTRATION:</b>	Initial dose: 60microgram/kg by IV injection over 3-5 minutes (Note please use ideal body weight).  Additional doses of 20-30microgram/kg can be given 1 - 1 ½ hourly if required.  Ideally administer via CVC or a large peripheral vein due to risk of venous irritation caused by low pH.  Can be given undiluted or in sodium chloride 0.9% or glucose 5% for ease of administration.
<b>CONCENTRATION:</b>	2mg/ml
<b>STABILITY:</b>	Physically and chemically stable for 24hours.
<b>ADDITIONAL INFORMATION:</b>	In common with all neuromuscular blocking agents, monitoring of neuromuscular function using train-of-four peripheral nerve stimulation, is recommended during the use of pancuronium in order to individualise dosage requirements.

### References

1. Pancuronium Bromide, Summary of Product Characteristics. Manufactured by Hospira UK Ltd. <https://www.medicines.org.uk/emc/product/3793/smpc> Accessed Jan 2022
2. Pancuronium Bromide, Injectable Medicines Guide <https://medusa.wales.nhs.uk/IVGuideDisplay.asp> Accessed Jan 2022
3. Pancuronium Bromide, Storage and Stability, Trissel, Micromedex. Accessed via Knowledge Network, May 2022

Title: Pancuronium	
ID:	Authors: Mairi Cromarty
Category:	Document Version: 2.0
Status Draft/Final: FINAL	Review Date: March 2024
Authoriser: Lothian Critical Care QIT Editorial Board	Authorisation Date: March 2022
Date added to Intranet:	
Key Words	
Comments	